research Conditional Disruption of Hedgehog Signaling Pathway Defines Its Critical Role in Hair Development and Regeneration
The hedgehog signaling pathway is crucial for hair growth but not for the initial creation of hair follicles.
Search
forLearn
0 / 0 results — no results
Research
5 / 428 results 
research Why Do Promising Therapies Stall in Development and How Can We Move Them Forward?
Most drugs fail to reach the market, but understanding their properties and using strategies like early toxicity tests and drug repurposing can help advance their development.
research Protein Kinase Cε Sensitizes Skin to UV Radiation-Induced Damage and Squamous Cell Carcinoma Development, Associates with Stat3
Protein Kinase Cε increases skin sensitivity to UV damage and skin cancer risk.
research Tinea Capitis in Benghazi, Libya
Tinea capitis in Benghazi mainly affects children under 10, with Trichophyton violaceum as the leading cause.
research Insulin Resistance and Obesity Among Infertile Women With Different Polycystic Ovary Syndrome Phenotypes
Women with PCOS are more likely to have insulin resistance and obesity, especially those with the most severe type I PCOS.
Community Join
5 / 84 resultscommunity People who moan that more important things than hair loss treatment should be researched need to shut the
Hair loss research is important and contributes to overall scientific advancement, benefiting emotional well-being and potentially aiding other medical fields. Treatments mentioned include PP405 and SCUBE3.
community Phase II for Technoderma Therepeutic's TDM-105795 set to begin in April tentatively
Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.
community Cosmo Pharmaceutical (Breezula) fiscal results. Top Line Six month results expected early in the second half of this year.
Clascoterone solution is in Phase III trials for male androgenetic alopecia, with results expected in the second half of 2025. Commercialization is anticipated in about 2-3 years, but there are concerns about delays and market expectations.
community Veradermics VDPHL01: why isn’t anyone talking about it?
Veradermics' new hair loss treatment, VDPHL01, is likely a modified release oral minoxidil, which has received $75 million in funding for clinical trials. Despite skepticism about investing in a known treatment, some believe it could offer improved efficacy and reduced side effects.
community Why TDM-105795 is not much talked about like GT20029 and HMI 115 despite having far better Trial results?
TDM-105795 showed better efficacy and safety in trials for hair loss, with a higher hair count improvement compared to GT20029 and HMI 115, but it's not as widely discussed. The user is questioning why this is the case.